SGLT-2 inhibitors and their potential in the treatment of diabetes

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Rebecca F RosenwasserBenjamin J Epstein

Abstract

Diabetes remains a burgeoning global problem, necessitating ongoing efforts on the part of pharmaceutical and device manufacturers, patients, and society to curb the frightening trends in morbidity and mortality attributable to the malady. Since 1835 when phlorizin was discovered, sodium glucose co-transporter 2 (SGLT-2) inhibitors have rested tantalizingly on the horizon, promising a more physiological approach to glucose control. These agents lower glucose by enhancing its excretion by blocking reabsorption in the renal tubules, thus eliminating glucose from the body along with the molecules' attendant effects on caloric balance, plasma osmolality, and lipids. Consequently, SGLT-2 inhibitors improve glucose control to an extent comparable to other hypoglycemic agents while simultaneously reducing body weight, blood pressure, and cholesterol - an admirable portfolio. One agent, canagliflozin, has recently been approved by the US Food and Drug Administration (FDA) and two other agents have progressed through Phase III trials, including dapagliflozin and empagliflozin. Collectively, when used as monotherapy, these agents have demonstrated reductions in hemoglobin A1c (HbA1c), body weight, and blood pressure of -0.34% to -1.03%, ...Continue Reading

Citations

May 23, 2014·Drugs·Raewyn M Poole, Jennifer E Prossler
Nov 5, 2014·Indian Journal of Endocrinology and Metabolism·Jayant KelwadeV Sri Nagesh
Jun 29, 2014·Advances in Therapy·Theodoros P Angelopoulos, John Doupis
Sep 26, 2014·International Journal of Endocrinology·Hao-Wen Lin, Chin-Hsiao Tseng
Nov 2, 2014·Clinical and Experimental Pharmacology & Physiology·Zhi-Xu HeShu-Feng Zhou
Apr 22, 2015·Clinical Therapeutics·Karen WhalenErin St Onge
Nov 4, 2016·Pediatric Diabetes·Fida Bacha, Sara Klinepeter Bartz
May 6, 2016·Frontiers in Endocrinology·Mussa H Almalki, Fahad Alshahrani
May 30, 2020·Postgraduate Medical Journal·Jovanna TsoutsoukiTahseen Ahmad Chowdhury
Jun 23, 2020·Journal of Diabetes·Itivrita GoyalParesh Dandona

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

Lexicon

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.